IMVT
NASDAQImmunovant Inc.
Price$31.19-0.92 (-2.87%)
01:30 PM07:45 PM
News · 26 weeks39+100%
2025-12-142026-06-07
Mix3090d
- Insider22(73%)
- SEC Filings4(13%)
- Earnings3(10%)
- Analyst1(3%)
Latest news
25 items- INSIDERDirector Fromkin Andrew J. exercised 196,601 shares at a strike of $8.22 and sold $7,438,111 worth of shares (221,951 units at $33.51), decreasing direct ownership by 25% to 74,382 units (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)
- SECSEC Form 144 filed by Immunovant Inc.144 - Immunovant, Inc. (0001764013) (Subject)
- INSIDERChief Operating Officer Gloria Melanie sold $101,072 worth of shares (3,115 units at $32.45), decreasing direct ownership by 1% to 242,107 units (SEC Form 4) to satisfy withholding obligation4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERDirector Pande Atul exercised 6,000 shares at a strike of $8.43 and sold $192,000 worth of shares (6,000 units at $32.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)
- SECSEC Form 144 filed by Immunovant Inc.144 - Immunovant, Inc. (0001764013) (Subject)
- SECSEC Form 10-K filed by Immunovant Inc.10-K - Immunovant, Inc. (0001764013) (Filer)
- SECImmunovant Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Immunovant, Inc. (0001764013) (Filer)
- PRImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) fully enrolled with topline data expected in the second half of calendar year 2026All other clinical development timelines remain on track for IMVT-1402, including potentially registrational studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren's disease (SjD)
- PRImmunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About Immunovant Immunova
- INSIDERDirector Susman Robert Graham sold $67,979 worth of shares (2,502 units at $27.17) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 36,394 units (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERChief Financial Officer Girao Tiago sold $763,011 worth of shares (25,760 units at $29.62), decreasing direct ownership by 9% to 247,596 units (SEC Form 4) (for withholding tax)4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERChief Technology Officer Stout Jay S sold $81,573 worth of shares (2,754 units at $29.62), decreasing direct ownership by 1% to 251,685 units (SEC Form 4) (tax withholding)4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Van Tuyl Christopher4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Gloria Melanie4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Stout Jay S4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Torti Frank4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Fromkin Andrew J.4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Hughes Douglas J.4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Pande Atul4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Bauer Jake4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Susman Robert Graham4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Gloria Melanie4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Stout Jay S4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Van Tuyl Christopher4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Venker Eric4 - Immunovant, Inc. (0001764013) (Issuer)
IMVT FAQ
7 questionsWhat does Immunovant Inc. do?
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of...Where does IMVT stock trade?
Immunovant Inc. (IMVT) is listed on NASDAQ.What sector and industry is IMVT in?
Immunovant Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Immunovant Inc. go public?
Immunovant Inc. (IMVT) completed its IPO in 2019.What are analysts saying about IMVT?
Immunovant Inc. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Mkt Perform with a $2800.00 price target on 2026-03-20. Recent price targets range from $1600.00 to $3600.00.What companies are similar to IMVT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare IMVT side-by-side with any of them on Quantisnow.How can I track IMVT on Quantisnow?
Quantisnow aggregates Immunovant Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMVT to receive live email and push alerts on every new disclosure.